Our research and development is based on two basic concepts. Due to an impact to the head, brain's biochemistry changes and a cascade of molecules are released into the surrounding fluid. Some of these molecules find their way to other body fluids.
The lack of a truly effective diagnostic test for brain injury is a major unmet need in modern medicine.
The main problem is that, while there are often tell-tale symptoms, many TBI victims do not present evident brain injury symptoms, and consequently receive treatment either too late or not at all. In addition, repeated mild TBI can lead to a condition called Chronic Traumatic Encephalopathy (CTE). Victims of CTE, who have lately been in the news due to their involvement in high profile athletics, still have no way of detecting or tracking their condition. Therefore, it is critical that a core group of TBI biomarkers be identified.
Medicortex has discovered new biomarkers that have never been studied before for detection of TBI, identifying them from one or more of the body fluids that have been less investigated for this purpose. The idea is to make a relatively easy test to be used, for example, in emergency response situations like car accidents, sport injuries and combat situations. It can also help in cases where the injured person cannot describe the injury such as babies and people in coma.
Medicortex is targeting glycoproteins and cellular proteins/enzymes, which are exposed to each other due to cells being damaged. We are looking for proteolytic breakdown products. This product can either increase or decrease following the injury, thus indicating the imbalance of the brain integrity.